Shorted
Invion logo
IVX
Pharmaceuticals, Biotechnology & Life Sciences

Invion

Short interest
0.01%
+0.01 pp 30d
as of 11 Feb 2025
Reported shorts
8.5K
Shares on issue
70.356M

Invion (IVX) company profile

Profile, insiders and operations

Company

AI-generated research profile of Invion

Pharmaceuticals
Biotechnology
Cancer Treatment
PhotoDynamic Therapy
Clinical Trials

Invion is a clinical-stage pharmaceutical company specializing in the development of PhotoDynamic Therapy (PDT) for cancer treatment. The company holds exclusive rights to the Photosoft technology in various regions, aiming to improve cancer treatment efficacy with minimal side effects.

Director trades

20 trades recorded

DateDirectorTypeSharesPriceValue
2026-06-19Unknown Director
buy
---
2026-06-12Alistair Bennallack
exercise options
3,340,458--
2026-05-11Alistair Bennallack
other
12,963--
2026-05-11Alistair Bennallack
buy
---
2026-04-20Unknown Director
buy
---
2026-04-20Chiat Thian Chew
other
5,488,637--
2026-04-20Thian Chew
buy
---
2025-09-24Thian Chew
buy
---
2025-09-23Chiat Thian Chew
other
1,384,886--
2025-07-24Alistair Bennallack
buy
---
2025-07-24Alan Yamashita
buy
---
2025-07-24Thian Chew
buy
---
2025-07-23Chiat Thian Chew
buy
14,210,806$0.015$213,162.09
2025-07-18Alan Yamashita
buy
115,541$0.015$1,733.12
2025-07-18Alistair Bennallack
buy
181,064$0.015$2,715.96
2025-06-25Alan Yamashita
buy
---
2025-06-25Alistair Bennallack
buy
---
2025-06-25Thian Chew
buy
---
2025-06-24Alan Yamashita
exercise options
41,411--
2025-06-24Chiat Thian Chew
exercise options
68,086--

IVX intelligence dossier

Public-source evidence for this company, with industry drill-up links.

  • Tax paid and taxable income records
  • Government contracts and public money
  • Emissions and trade exposure
  • Political donations and lobbying links
Sign in to unlock the dossierFree account · no card required